// App-Quantinova.ai

2934 : Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial

Researchers

Presenter

  • Pier Luigi Zinzani

Principal Investigators

  • Wojciech Jurczak

  • Nilanjan Ghosh

  • Enrico Derenzini

  • James A Reeves

  • Wanda Knopinska-Posluszny

  • Chan Yoon Cheah

  • Tycel J. Phillips

  • Ewa Lech-Maranda

  • Bruce D. Cheson

  • Paolo F Caimi

  • Sebastian Grosicki

  • Lori A. Leslie

  • Julio C. Chavez

  • Gustavo A. Fonseca

  • Sunil Babu

  • Daniel J. Hodson

  • Spencer H. Shao

  • John M. Burke

  • Jeff P Sharman

  • Jennie Y. Law

  • John M. Pagel

  • Owen A. O'Connor

  • Hari P. Miskin

  • Peter Sportelli

  • Michael S. Weiss

  • Nathan H Fowler

Medical Centers

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • Department of Hematology, Lymphoma Division, Levine Cancer Institute, Charlotte, NC

  • Hematoncology, European Instituo of Oncology, Milan, Italy

  • Florida Cancer Specialists South / Sarah Cannon Research Institute, Ft Myers, FL

  • Gdynia Oncology Center, Gdynia, Poland

  • Linear Clinical Research/Sir Charles Gairdner Hospital, Nedlands, Australia

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • Department of Hematology, Institute of Hematology and Transfusion Medicine, Warszawa,

  • Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

  • Adult Hematologic Malignancies & Stem Cell Transplant Program, University Hospitals, Seidman Cancer Center, Cleveland, OH

  • Department of Hematology and Cancer Prevention,Health Sciences Faculty, Medical University of Silesia,Katowice,Poland

  • John Theurer Cancer Centre, Hackensack University Medical Center, Hackensack, NJ

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

  • Florida Cancer Specialists, St. Petersburg, FL

  • Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN

  • Wellcome Trust-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom

  • Compass Oncology, US Oncology Research, Tualatin, OR

  • US Oncology Hematology Research Program, Rocky Mountain Cancer Centers,Aurora,Stati Uniti

  • Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR

  • Division of Hematology/Oncology, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD

  • Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute,Seattle,Estados Unidos

  • Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY

  • TG Therapeutics, Inc., New York, NY

Locations

  • Italy

  • United States

  • Poland

  • Australia

  • United Kingdom

Companies

  • TG Therapeutics, Inc

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pneumocystis Jiroveci Pneumonia

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Follicular lymphoma

  • Hodgkin's Lymphoma

  • Lymphomas

Biomarkers

  • Bone Morphogenetic Protein 1

  • Transthyretin

Drug/Treatment

  • Umbralisib

  • Casein

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02793583

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved